by Gertrud U. Rey The antiviral drug Paxlovid is highly effective at inhibiting SARS-CoV-2 replication and reducing symptoms associated with COVID-19. Nevertheless, there have recently been numerous reports of recurrence of positive tests and symptoms after completing treatment with Paxlovid, leading some to infer that the drug triggers the recurrence. Is this inference actually correct, …
Although monkeypox cases continue to increase around the world, the average person is at low risk of becoming infected.
TWiV explains what is known about cases of acute, severe hepatitis of unknown origin in children, and discovery of an inhibitor of TMPRSS2 protease that blocks SARS-CoV-2 infection.
Richard joins TWiV to discuss the SARS-CoV-2 antiviral drug Molnupiravir , including how it was discovered, its mechanism of action, whether it is a mutagen for cells, and the future of drugs for treatment of COVID-19.
Molnupiravir might be the first highly effective antiviral drug given emergency use authorization for treatment of COVID-19. Should we be concerned about the results of a recent study which show that the drug is mutagenic in cells? Molnupiravir is an orally available pro-drug of the nucleoside analog N4-hydroxycytidine (NHC). The latter is a nucleoside analogue …
On this episode, FDA EUA for Pfizer mRNA vaccine, efficacy of AstraZeneca ChAdOx1 COVID-19 vaccine, and an orally administered drug that blocks SARS-CoV-2 transmission in ferrets. Hosts: Vincent Racaniello, Dickson Despommier, Alan Dove, Rich Condit, and Brianne Barker Click arrow to playDownload TWiV 693 (69 MB .mp3, 115 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv